Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 192

Results For "GE"

8966 News Found

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients
News | March 20, 2026

Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients

India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease


Pfizer drug candidate shows strong results in tough breast cancer study
Clinical Trials | March 19, 2026

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged


Zydus and Torrent Pharma to co-market Semaglutide injection in India
News | March 19, 2026

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device


Mankind Pharma acquires Rivotril brand for India
News | March 19, 2026

Mankind Pharma acquires Rivotril brand for India

Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions


Alcon walks away from LENSAR deal after regulatory roadblock
News | March 19, 2026

Alcon walks away from LENSAR deal after regulatory roadblock

At the center of the collapse is opposition from the Federal Trade Commission


Trial milestone sparks hope for first long-term gastroparesis treatment
Clinical Trials | March 19, 2026

Trial milestone sparks hope for first long-term gastroparesis treatment

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis


Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students
News | March 19, 2026

Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students

SPARK has extended its influence to an additional 9.47 million students worldwide


Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
Drug Approval | March 18, 2026

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options